103 related articles for article (PubMed ID: 26051901)
1. Selective inhibition of the hypoxia-inducible factor prolyl hydroxylase PHD3 by Zn(II).
Na YR; Woo DJ; Choo H; Chung HS; Yang EG
Chem Commun (Camb); 2015 Jul; 51(53):10730-3. PubMed ID: 26051901
[TBL] [Abstract][Full Text] [Related]
2. Pyrithione Zn selectively inhibits hypoxia-inducible factor prolyl hydroxylase PHD3.
Na YR; Woo DJ; Kim SY; Yang EG
Biochem Biophys Res Commun; 2016 Apr; 472(2):313-8. PubMed ID: 26940742
[TBL] [Abstract][Full Text] [Related]
3. Photoactivatable Prolyl Hydroxylase 2 Inhibitors for Stabilizing the Hypoxia-Inducible Factor with Light.
Li Z; Su K; Jiang Z; Yu Y; You Q; Zhang X
J Med Chem; 2019 Aug; 62(16):7583-7588. PubMed ID: 31244107
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of prolyl hydroxylase 3 ameliorates cardiac dysfunction in diabetic cardiomyopathy.
Xia Y; Gong L; Liu H; Luo B; Li B; Li R; Li B; Lv M; Pan J; An F
Mol Cell Endocrinol; 2015 Mar; 403():21-9. PubMed ID: 25595486
[TBL] [Abstract][Full Text] [Related]
5. Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors.
Deng G; Zhao B; Ma Y; Xu Q; Wang H; Yang L; Zhang Q; Guo TB; Zhang W; Jiao Y; Cai X; Zhang J; Liu H; Guan X; Lu H; Xiang J; Elliott JD; Lin X; Ren F
Bioorg Med Chem; 2013 Nov; 21(21):6349-58. PubMed ID: 24055079
[TBL] [Abstract][Full Text] [Related]
6. Application of in-vitro screening methods on hypoxia inducible factor prolyl hydroxylase inhibitors.
Wu Y; Jiang Z; You Q; Zhang X
Bioorg Med Chem; 2017 Aug; 25(15):3891-3899. PubMed ID: 28625716
[TBL] [Abstract][Full Text] [Related]
7. Prolyl-hydroxylase PHD3 interacts with pyruvate dehydrogenase (PDH)-E1β and regulates the cellular PDH activity.
Kikuchi D; Minamishima YA; Nakayama K
Biochem Biophys Res Commun; 2014 Aug; 451(2):288-94. PubMed ID: 25088999
[TBL] [Abstract][Full Text] [Related]
8. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of prolyl 4-hydroxylases by bipyridinedicarboxylates.
Vasta JD; Raines RT
Bioorg Med Chem; 2015 Jul; 23(13):3081-90. PubMed ID: 26022078
[TBL] [Abstract][Full Text] [Related]
10. ExActa HIF prolyl hydroxylase inhibitors-The new lifestyle drug?
Sciesielski LK; Kirschner KM
Acta Physiol (Oxf); 2019 Nov; 227(3):e13370. PubMed ID: 31465609
[No Abstract] [Full Text] [Related]
11. Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.
Fukuda T; Kuribayashi T; Takano R; Sasaki K; Tsuji T; Niitsu Y; Ishii K; Hashimoto M; Baba D; Ito S; Tanaka N
Bioorg Med Chem Lett; 2024 Aug; 108():129799. PubMed ID: 38754564
[TBL] [Abstract][Full Text] [Related]
12. Structure-Activity Relationship and Crystallographic Studies on 4-Hydroxypyrimidine HIF Prolyl Hydroxylase Domain Inhibitors.
Holt-Martyn JP; Chowdhury R; Tumber A; Yeh TL; Abboud MI; Lippl K; Lohans CT; Langley GW; Figg W; McDonough MA; Pugh CW; Ratcliffe PJ; Schofield CJ
ChemMedChem; 2020 Feb; 15(3):270-273. PubMed ID: 31751494
[TBL] [Abstract][Full Text] [Related]
13. Structure-based drug design for hypoxia-inducible factor prolyl-hydroxylase inhibitors and its therapeutic potential for the treatment of erythropoiesis-stimulating agent-resistant anemia: raising expectations for exploratory clinical trials.
Higashijima Y; Tanaka T; Nangaku M
Expert Opin Drug Discov; 2013 Aug; 8(8):965-76. PubMed ID: 23642028
[TBL] [Abstract][Full Text] [Related]
14. Prolyl hydroxylase 3 inhibited the tumorigenecity of gastric cancer cells.
Cui L; Qu J; Dang S; Mao Z; Wang X; Fan X; Sun K; Zhang J
Mol Carcinog; 2014 Sep; 53(9):736-43. PubMed ID: 23533015
[TBL] [Abstract][Full Text] [Related]
15. Investigating the contribution of the active site environment to the slow reaction of hypoxia-inducible factor prolyl hydroxylase domain 2 with oxygen.
Tarhonskaya H; Chowdhury R; Leung IK; Loik ND; McCullagh JS; Claridge TD; Schofield CJ; Flashman E
Biochem J; 2014 Nov; 463(3):363-72. PubMed ID: 25120187
[TBL] [Abstract][Full Text] [Related]
16. Prolyl hydroxylase 3 stabilizes the p53 tumor suppressor by inhibiting the p53-MDM2 interaction in a hydroxylase-independent manner.
Xu Y; Gao Q; Xue Y; Li X; Xu L; Li C; Qin Y; Fang J
J Biol Chem; 2019 Jun; 294(25):9949-9958. PubMed ID: 31092600
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
[TBL] [Abstract][Full Text] [Related]
18. Oxygen sensors as therapeutic targets in kidney disease.
Haase VH
Nephrol Ther; 2017 Apr; 13 Suppl 1():S29-S34. PubMed ID: 28577740
[TBL] [Abstract][Full Text] [Related]
19. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia.
HoWangYin KY; Loinard C; Bakker W; Guérin CL; Vilar J; d'Audigier C; Mauge L; Bruneval P; Emmerich J; Lévy BI; Pouysségur J; Smadja DM; Silvestre JS
Stem Cells; 2014 Jan; 32(1):231-43. PubMed ID: 24105925
[TBL] [Abstract][Full Text] [Related]
20. Microbiota-derived butyrate is an endogenous HIF prolyl hydroxylase inhibitor.
Wang RX; Henen MA; Lee JS; Vögeli B; Colgan SP
Gut Microbes; 2021; 13(1):1938380. PubMed ID: 34190032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
